"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients ...

FARMINGTON HILLS, Mich. – A stretch of Middlebelt Road and 8 Mile in Oakland County remains closed early Tuesday morning following a chemical spill. A hazmat team responded to an acid leak from ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

Enhertu logged sales of $3.75 billion in Daiichi’s 2024 fiscal year, which concluded at the end of March. The company is projecting sales of the treatment to reach 662 billion Japanese yen in ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

GALENA PARK, Texas (KTRK) -- The Targa Resources dock on the Houston Ship Channel has reopened after a chemical leak was reported on Tuesday. Targa Resources said that a valve malfunction happened ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

By then, AstraZeneca and cancer drug partner Daiichi Sankyo had already validated the blockbuster potential of HER2-directed ADCs with Enhertu. But Eisai identified BB-1701 as a potential best-in ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

The European chemical industry is in dire straits. Several major firms are on the verge of closing plants in the face of weak demand, persistently high natural gas prices, and a looming trade war.

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...